Pharmacy Times

SEPTEMBER 13, 2023

Senate Bill 219 will also allow pharmacists to independently administer influenza and COVID-19 tests waived by the clinical laboratory improvement amendments.

Vaccines 73

Vaccines 73

Hospital Pharmacy Europe

SEPTEMBER 25, 2023

The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19, have been presented at the recent European Scientific Working Group on Influenza and other Acute Respiratory Viruses’ (ESWI) Influenza Conference.

Hospitals 126

Hospitals FDA 126

European Pharmaceutical Review

FEBRUARY 26, 2024

Clinical data showed approximately 60 percent reductions in plasma NfL concentrations in patients given Qalsody compared to placebo. After 12 weeks, patients treated with danicopan had a clinically-relevant increase in haemoglobin (an average of 2.35 This indicated reduced neuronal injury, EMA noted.

Generic Medicine 94

Generic Medicine Pharmaceutical Companies Pharmaceutical Companies Vaccines 94

European Pharmaceutical Review

DECEMBER 18, 2023

Research at the Novo Nordisk Foundation Initiative for Vaccines and Immunity, or NIVI, will focus initially on creating new or improved vaccines for tuberculosis, influenza , and Group A Streptococcus (GAS). Collectively, these diseases cause more than 2.5 million deaths per year, according to the Novo Nordisk Foundation.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

JULY 18, 2022

GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. The latest contract comes after previous agreements between the parties for seasonal influenza and pandemic vaccines dating back to 2001.

Vaccines 64

Vaccines Immunization 64

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Hospitals 40

Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunization Hospitals 40

STAT

NOVEMBER 22, 2022

With this year’s flu season beginning some six weeks early , the CDC has already declared a flu epidemic as hospitalizations for influenza soared to the highest point in more than a decade. A storm of these proportions should demand not only crisis clinical measures, but also community prevention efforts. is abandoning them.

Hospitals 145

Hospitals 145

Hospital Pharmacy Europe

OCTOBER 12, 2023

The ongoing phase 1/2 clinical trial is a randomised, observer blind study evaluating the safety and immunogenicity of mRNA-1083 compared to a standard dose influenza vaccine (Fluarix) in adults 50-64 years of age and against an enhanced influenza vaccine (Fluzone HD) in adults 65-79 years of age.

Vaccines 59

Vaccines Hospitals 59

Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

Patient Care 115

Patient Care Immunization Vaccines 115

Pharmaceutical Technology

APRIL 14, 2023

The US Food and Drug Administration (FDA) has granted Fast Track designation to SAB Biotherapeutics’ SAB-176 to treat high-risk Type A and Type B influenza illness patients, including those with antiviral-resistant strains. We are excited about the potential role SAB-176 can play in tackling a highly mutagenic pathogen like influenza.”

FDA 52

FDA 52

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. Osivax’s influenza vaccine is in phase 2A studies. SARS-CoV-2.

Vaccines 97

Vaccines Immunization 97

Pharmafile

MARCH 22, 2023

Published date: 22/03/2023 Summary: VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

52

52

Pharmaceutical Technology

DECEMBER 20, 2023

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

FLU-SV-mRNA is under clinical development by Curevac and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According…

40

40

PharmaShots

MARCH 22, 2023

China, Hong Kong & Macao by undertaking all costs of clinical trials Reduced virus load and pharmacokinetics in flu-infected animals and patients show excellent performance in both pre-clinical & clinical trial data with TG-1000 treatment.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections.

52

52

pharmaphorum

FEBRUARY 18, 2021

The big UK pharma is already working with Vir on antibody therapies for coronaviruses, and already have the antibody VIR-7831 in clinical trials including the US National Institutes of Health-backed ACTIV-3 study. As part of the new collaboration agreement, the companies will also engage in two additional research programmes.

111

111

Pharmafile

APRIL 12, 2023

Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for COVID-19, influenza and respiratory syncytial virus (RSV), amongst others.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

SEPTEMBER 20, 2023

Three sa-mRNA vaccines used in the clinical trial enabled participants to maintain elevated immune response through 12 months post-vaccination. This promising data was presented at the European Scientific Working Group on Influenza’s 9th ESWI Influenza Conference in Spain.

Vaccines 96

Vaccines Immunization 96

The People's Pharmacy

JUNE 1, 2023

There is also evidence to suggest that influenza vaccines can prevent heart attacks and deaths from cardiovascular disease. Influenza Vaccines vs. Heart Attacks: We have been fairly critical about flu shots. Here is just one of our more recent rants about influenza vaccines.

Vaccines 87

Vaccines 87

Digital Pharmacist

AUGUST 21, 2023

Understanding the Flu and Its Impact Before getting into preparations, let’s establish a foundational understanding of influenza. The Centers for Disease Control and Prevention (CDC) defines the flu as a contagious respiratory illness caused by influenza viruses that target the nose, throat, and occasionally the lungs.

Vaccines 98

Vaccines Communication Immunization 98

European Pharmaceutical Review

NOVEMBER 29, 2022

The adaptive platform trial to study influenza. National Institute for Health and Care Research (NIHR)’s Clinical Research Network. The post First adaptive clinical trial for flu appeared first on European Pharmaceutical Review. The initiative is delivered by the ?National

Hospitals 102

Hospitals Vaccines 102

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. ” Hensley et al say they are currently designing human clinical trials of the vaccine candidate. are not similar.”

Vaccines 105

Vaccines Immunization 105

pharmaphorum

JULY 21, 2022

A COVID-19 vaccine developed using the technology cleared a phase 1 proof-of-concept study in Australia, but Vicebio is focusing first on RSV, with clinical trials of VXB-211 scheduled to in the second half of next year. ” He said. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. .

Vaccines 104

Vaccines Immunization 104

Hospital Pharmacy Europe

FEBRUARY 16, 2023

In fact, work from 2012 showed that the use of a TLR-2 agonist in mice offered protection against influenza. Given the important role of TLRs in the earliest phase of a host’s immune response, the development of TLR agonists is a promising therapeutic strategy.

Immunization 52

Immunization Hospitals Vaccines 52

European Pharmaceutical Review

AUGUST 17, 2023

NIH’s vaccine candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials, produced in an A549 cell line. Intranasal vaccines have previously been used to immunise against conditions such as respiratory viruses, measles and rubella.

Vaccines 93

Vaccines Immunization 93

PharmaShots

APRIL 13, 2023

Shots: The US FDA has granted FTD to SAB-176 for high-risk patients with Type A & B influenza illness incl. of clinical & pre-clinical studies has been conducted on SAB-176, incl. those who have anti-viral resistant strains A no. a P-I trial in healthy volunteers & a P-IIa challenge study.

FDA 40

FDA 40

The People's Pharmacy

MAY 1, 2023

The FDA has approved three prescription medicines for treating influenza , but one is reserved for hospitalized patients. Like elderberry ( Sambucus nigra ) , the Chinese herb Andrographis paniculata has a reputation for speeding recovery from influenza. Moreover, their effectiveness can vary quite a bit. Is this warranted?

Immunization 56

Immunization Hospitals FDA 56

Digital Pharmacist

AUGUST 31, 2023

Whether addressing acute pharyngitis, influenza, COVID-19, or other respiratory infections, the ability to swiftly identify causative agents empowers healthcare providers to make informed decisions that significantly impact patient outcomes. However, influenza testing informs antibiotic vs. antiviral treatment and care decisions.

Independent Pharmacies 52

Independent Pharmacies Scheduling Appointments Hospitals Communication 52

pharmaphorum

JANUARY 18, 2022

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus. We look forward to updating the market as POLB 002 progresses through the clinic with the ultimate aim of partnering it with Big Pharma.”.

Vaccines 58

Vaccines 58

Hospital Pharmacy Europe

SEPTEMBER 11, 2023

Guidance on how global warming can be addressed in clinical practice has been outlined by the European Respiratory Society (ERS) in its latest consensus statement on climate change and respiratory health.

Hospitals 105

Hospitals 105

Digital Pharmacist

JULY 11, 2023

One effective strategy to achieve this is by offering top-notch clinical services that not only enhance patient care but also contribute to a significant revenue boost. Digital Marketing Services Our digital marketing services are designed to promote your clinical services effectively.

Independent Pharmacies 98

Independent Pharmacies Compounding Scheduling Appointments Prescription Filling 98

pharmaphorum

DECEMBER 1, 2021

The vaccine has just started clinical testing, but is designed to control the growth of C acnes on the skin and prevent it from damaging the cellular lining of pores, which can lead to scarring in severe acne cases. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.

Vaccines 105

Vaccines FDA 105

pharmaphorum

JULY 7, 2022

The institute also led and funded early-stage clinical research into the vaccine candidate. A recently published paper identified within this lists three viruses that were deemed the most likely to cause another outbreak: coronavirus, influenza virus, and Ebola virus disease. Research defence.

Vaccines 104

Vaccines Immunization 104

pharmaphorum

NOVEMBER 2, 2022

Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other respiratory pathogens, including those that may cause future pandemics.

Vaccines 52

Vaccines Immunization 52